No CrossRef data available.
Cost-effectiveness of population-based screening for microalbuminuria in people with type 2 diabetes mellitus in India
Published online by Cambridge University Press: 14 November 2023
Abstract
Objectives
Patients with diabetes have a higher risk of developing chronic kidney disease (CKD). Early detection of CKD through microalbuminuria screening, followed by treatment, delays the progression of CKD. We evaluated the cost-effectiveness of population-based screening of microalbuminuria among normotensive type 2 diabetes mellitus patients aged >40 years compared with no screening scenario using a decision tree combined with the Markov model.
Methods
We considered two scenarios: Scenario I – dipstick microalbuminuria followed by spot-urine albumin–creatinine ratio (ACR) and serum creatinine in sequence; Scenario II – spot urine ACR plus serum creatinine. A mathematical cohort of the target population was simulated over a lifetime horizon with an annual cycle. Data for the model were obtained from secondary resources. The incremental cost-effectiveness ratios (ICERs) were estimated for screening scenarios compared to nonscreening scenario, along with sensitivity analyses.
Results
The discounted ICER per quality-adjusted life years gained for annual microalbuminuria screening in the normotensive diabetic population in India were ₹ 24,114 (US$ 308) and ₹ 13,790 (US$ 176) for scenarios I and II, respectively. Annual screening by scenarios I and II resulted in a reduction of 180 and 193 end-stage renal disease (ESRD) cases per 100,000 population, respectively, resulting in a cost saving of ₹ 12.3 and 13.3 Crore spent on ESRD management over 10 years. Both scenarios were also cost-effective even at the screening frequencies of 5 and 10 yearly.
Conclusion
Microalbuminuria screening was cost-effective at the threshold of one-time GDP per capita in India.
Keywords
- Type
- Assessment
- Information
- Copyright
- © The Author(s), 2023. Published by Cambridge University Press
References
Chonchol, M, Lippi, G, Salvagno, G, et al. Prevalence of subclinical hypothyroidism in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2008;3(5):1296–1300. doi:10.2215/CJN.00800208.CrossRefGoogle ScholarPubMed
Kovesdy, CP. Epidemiology of chronic kidney disease: An update 2022. Kidney Int Suppl. 2022;12(1):7–12. doi:10.1016/j.kisu.2021.11.003.CrossRefGoogle ScholarPubMed
GBD 2019 Diseases and Injuries Collaborators . Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: A systematic analysis for the global burden of disease study 2019
Lancet.
2020;396(10258):1204–1222. doi:10.1016/S0140-6736(20)30925-9.CrossRefGoogle Scholar
Anjana, RM, Deepa, M, Pradeepa, R, et al. Prevalence of diabetes and prediabetes in 15 states of India: Results from the ICMR-INDIAB population-based cross-sectional study. Lancet Diabetes Endocrinol. 2017;5(8):585–596. doi:10.1016/S2213-8587(17)30174-2.CrossRefGoogle ScholarPubMed
Ene-Iordache, B, Perico, N, Bikbov, B, et al. Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): A cross-sectional study. Lancet Glob Health. 2016;4(5):e307–e319. doi:10.1016/S2214-109X(16)00071-1.CrossRefGoogle ScholarPubMed
Koye, DN, Magliano, DJ, Nelson, RG, Pavkov, ME. The global epidemiology of diabetes and kidney disease. Adv Chronic Kidney Dis. 2018;25(2):121–132. doi:10.1053/j.ackd.2017.10.011.CrossRefGoogle ScholarPubMed
Prasannakumar, M, Rajput, R, Seshadri, K, et al. An observational, cross-sectional study to assess the prevalence of chronic kidney disease in type 2 diabetes patients in India (START -India). Indian J Endocrinol Metab. 2015;19(4):520–523. doi:10.4103/2230-8210.157857.Google ScholarPubMed
Parameswaran, S, Geda, SB, Rathi, M, et al. Referral pattern of patients with end-stage renal disease at a public sector hospital and its impact on outcome. Natl Med J India. 2011;24(4):208–213.Google Scholar
Pradhan Mantri National Dialysis Programme under NHM_0.pdf [Online]. Available from: https://main.mohfw.gov.in/sites/default/files/Pradhan%20Mantri%20National%20Dialysis%20Programme%20under%20NHM_0.pdf. Accessed September 3, 2022.Google Scholar
Khan, A, Jan, F, Rashid, H. Prevalence of distress financing and catastrophic health expenditure among end stage renal disease patients attending a tertiary care teaching Hospital of North India. BJSTR. 2021;32:25133. doi:10.26717/BJSTR.2020.32.005275.Google Scholar
Idowu, AA, Ajose, AO, Adedeji, AT, Adegoke, AO, Jimoh, KA. Microalbuminuria, other markers of nephropathy and biochemical derangementsin type 2 diabetes mellitus: Relationships and determinants. Ghana Med J. 2017;51(2):56–63.Google Scholar
Molitch, ME, Adler, AI, Flyvbjerg, A, et al. Diabetic kidney disease: A clinical update from kidney disease: Improving global outcomes. Kidney Int. 2015;87(1):20–30. doi:10.1038/ki.2014.128.CrossRefGoogle ScholarPubMed
Directorate General Of Health Services. Available from: https://dghs.gov.in/content/1363_3_NationalProgrammePreventionControl.aspx. Accessed September 3, 2022.Google Scholar
Hoerger, TJ, Hoerger, TJ, Wittenborn, JS, et al. A health policy model of CKD: 2. The cost-effectiveness of microalbuminuria screening. Am J Kidney Dis. 2010;55(3):463–473. doi:10.1053/j.ajkd.2009.11.017.CrossRefGoogle ScholarPubMed
Kuritzky, L, Toto, R, Van Buren, P. Identification and management of albuminuria in the primary care setting. J Clin Hypertens (Greenwich). 2011;13(6):438–449. doi:10.1111/j.1751-7176.2010.00424.x.CrossRefGoogle ScholarPubMed
Nagrebetsky, A, Jin, J, Stevens, R, et al. Diagnostic accuracy of urine dipstick testing in screening for microalbuminuria in type 2 diabetes: A cohort study in primary care. Fam Pract. 2013;30(2):142–152. doi:10.1093/fampra/cms057.CrossRefGoogle ScholarPubMed
Power, M, Fell, G, Wright, M. Principles for high-quality, high-value testing. Evid Based Med. 2013;18(1):5–10. doi:10.1136/eb-2012-100645.CrossRefGoogle ScholarPubMed
Lepore, G, Maglio, ML, Nosari, I, Dodesini, AR, Trevisan, R. Cost-effectiveness of two screening programs for microalbuminuria in type 2 diabetes
Diabetes Care.
2002;25(11):2103–2104; author reply 2104. doi:10.2337/diacare.25.11.2103.CrossRefGoogle ScholarPubMed
Srisubat, A, Sriratanaban, J, Ngamkiatphaisan, S, Tungsanga, K. Original article. Cost-effectiveness of annual microalbuminuria screening in Thai diabetics. Asian Biomedicine. 2014;8(3):371–379.CrossRefGoogle Scholar
Kaur, G, Chauhan, AS, Prinja, S, et al. Cost-effectiveness of population-based screening for diabetes and hypertension in India: An economic modelling study. Lancet Public Health. 2022;7(1):e65–e73. doi:10.1016/S2468-2667(21)00199-7.CrossRefGoogle ScholarPubMed
Sivanantham, P, Sahoo, J, Lakshminarayanan, S, Bobby, Z, Kar, SS. Profile of risk factors for non-communicable diseases (NCDs) in a highly urbanized district of India: Findings from Puducherry district-wide STEPS survey, 2019–20. PLoS One. 2021;16(1):e0245254. doi:10.1371/journal.pone.0245254.CrossRefGoogle Scholar
Kaur, G, Prinja, S, Ramachandran, R, et al. Cost of hemodialysis in a public sector tertiary hospital of India. Clin Kidney J. 2018;11(5):726–733. doi:10.1093/ckj/sfx152.CrossRefGoogle Scholar
Jitraknatee, J, Ruengorn, C, Nochaiwong, S. Prevalence and risk factors of chronic kidney disease among type 2 diabetes patients: A cross-sectional study in primary care practice. Sci Rep. 2020;10(1):1. doi:10.1038/s41598-020-63443-4.CrossRefGoogle ScholarPubMed
Anandraj, KSSJ. Health-related quality of life among the patients undergoing dialysis in a tertiary care teaching hospital in southern India. Puducherry: Jawaharlal Institute of Postgraduate Medical Education and Research.Google Scholar
Prinja, S, Chauhan, AS, Bahuguna, P, et al. Cost of delivering secondary healthcare through the public sector in India. PharmacoEconomics Open. 2020;4(2):249–261. doi:10.1007/s41669-019-00176-9.CrossRefGoogle ScholarPubMed
Jeloka, TK, Upase, S, Chitikeshi, S. Monthly cost of three exchanges a day peritoneal dialysis is same as of thrice a week hemodialysis in self-paying Indian patients. Indian J Nephrol. 2012;22(1):39–41. doi:10.4103/0971-4065.83739.CrossRefGoogle Scholar
Adler, AI, Stevens, RJ, Manley, SE, et al. Development and progression of nephropathy in type 2 diabetes: The United Kingdom prospective diabetes study (UKPDS 64). Kidney Int. 2003;63(1):225–232. doi:10.1046/j.1523-1755.2003.00712.x.CrossRefGoogle ScholarPubMed
Mohan, V, Shanthirani, CS, Deepa, M, et al. Mortality rates due to diabetes in a selected urban south Indian population--the Chennai urban population study [CUPS--16]. J Assoc Physicians India. 2006;54:113–117.Google Scholar
ORGI SRS | Government of India. Available from: https://censusindia.gov.in/census.website/node/294. Accessed August 26, 2022.Google Scholar
Jyani, G, Sharma, A, Prinja, S, et al. Development of an EQ-5D value set for India using an extended design (DEVINE) study: The Indian 5-level version EQ-5D value set. Value Health. 2022;25(7):1218–1226. doi:10.1016/j.jval.2021.11.1370.CrossRefGoogle Scholar
Ahlawat, R, Tiwari, P, D’Cruz, S. Direct cost for treating chronic kidney disease at an outpatient setting of a tertiary hospital: Evidence from a cross-sectional study. Value Health Reg Issues. 2017;12:36–40. doi:10.1016/j.vhri.2016.10.003.CrossRefGoogle ScholarPubMed
Wang, H, Yang, L, Wang, F, Zhang, L. Strategies and cost-effectiveness evaluation of persistent albuminuria screening among high-risk population of chronic kidney disease. BMC Nephrol. 2017;18:135. doi:10.1186/s12882-017-0538-1.CrossRefGoogle ScholarPubMed
Wu, B, Zhang, S, Lin, H, Mou, S. Prevention of renal failure in Chinese patients with newly diagnosed type 2 diabetes: A cost‐effectiveness analysis. J Diabetes Investig. 2018;9(1):152–161. doi:10.1111/jdi.12653.CrossRefGoogle ScholarPubMed
Kondo, M, Yamagata, K, Hoshi, SL, et al. Cost-effectiveness of chronic kidney disease mass screening test in Japan. Clin Exp Nephrol. 2012;16(2):279–291. doi:10.1007/s10157-011-0567-1.CrossRefGoogle ScholarPubMed
Go, D-S, Kim, S-H, Park, J, et al. Cost-utility analysis of the National Health Screening Program for chronic kidney disease in Korea. Nephrology (Carlton). 2019;24(1):56–64. doi:10.1111/nep.13203.CrossRefGoogle ScholarPubMed
Komenda, P, Ferguson, TW, Macdonald, K, et al. Cost-effectiveness of primary screening for CKD: A systematic review. Am J Kidney Dis. 2014;63(5):789–797. doi:10.1053/j.ajkd.2013.12.012.CrossRefGoogle ScholarPubMed
Ferguson, TW, Tangri, N, Tan, Z, et al. Screening for chronic kidney disease in Canadian indigenous peoples is cost-effective. Kidney Int. 2017;92(1):192–200. doi:10.1016/j.kint.2017.02.022.CrossRefGoogle ScholarPubMed
Mathan Kumar et al. supplementary material
File
313.4 KB